Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + pertuzumab/trastuzumab SC + nab-paclitaxel neoadjuvant therapy in HER2-positive stage II–III breast cancer
ChiCTR2500108585Phase 2Recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, pertuzumab, trastuzumab, paclitaxel and trastuzumab emtansine in breast cancer, sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Total pathological complete response (tpCR). Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500108585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108585.